Smith & Nephew plc (LON:SN) Declares Dividend of $0.23

Smith & Nephew plc (LON:SN) declared a dividend on Tuesday, February 27th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.23 per share on Wednesday, May 22nd. This represents a yield of 1.62%. The ex-dividend date is Thursday, March 28th. This is a positive change from Smith & Nephew’s previous dividend of $0.14. The official announcement can be accessed at this link.

Smith & Nephew Stock Up 1.4 %

SN stock opened at GBX 1,032.50 ($13.05) on Wednesday. The company has a 50 day moving average of GBX 1,088.56 and a 200-day moving average of GBX 1,041.89. The company has a debt-to-equity ratio of 59.11, a quick ratio of 0.84 and a current ratio of 1.77. The firm has a market capitalization of £9.03 billion, a P/E ratio of 4,243.75, a PEG ratio of 0.55 and a beta of 0.51.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SN shares. JPMorgan Chase & Co. reissued an “overweight” rating and set a GBX 1,248 ($15.77) price target on shares of Smith & Nephew in a report on Thursday, November 30th. Barclays reaffirmed an “equal weight” rating and set a GBX 1,150 ($14.53) target price on shares of Smith & Nephew in a research note on Friday, February 9th. Finally, Berenberg Bank reiterated a “buy” rating and issued a GBX 1,500 ($18.96) price target on shares of Smith & Nephew in a research note on Thursday, November 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 1,349.50 ($17.05).

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.